Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.34 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.34 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23878153 | 0.80 | — | — | |
| SCHEMBL28438507 | 0.77 | CES2 (0.34) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL27853655 | 0.76 | OPRM1 (0.41) | HDAC4 | |
| SCHEMBL25564135 | 0.75 | DRD2 (0.37) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL25564232 | 0.73 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL25564311 | 0.73 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL16908880 | 0.73 | FPR2 (0.40) | HDAC1 | |
| SCHEMBL25564314 | 0.73 | HDAC3 (0.37) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL24112626 | 0.72 | SLC6A4 (0.43) | HDAC3HDAC1HDAC2HDAC6HCAR3 | |
| SCHEMBL25574870 | 0.71 | HDAC3 (0.33) | HDAC3HDAC1HDAC2HDAC6HCAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2024-02-01 | — | — | US | disclosed |
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | WUHAN LL SCIENCE & TECHNOLOGY DEVELOPMENT CO LTD (CN) | 2023-03-02 | — | — | US | disclosed |
| EP-3889154-A1 | HETEROCYCLIC COMPOUND INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-10-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230068538-A1 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | HDAC3 2505/4885HDAC1 3602/4885HDAC2 2889/4885 |
| US-20240034729-A9 | HETEROCYCLIC COMPOUND, INTERMEDIATE, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | P2RX3, P2RX7, P2RX4 | HDAC3 2505/4885HDAC1 3602/4885HDAC2 2889/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.